The discovery and optimization of antibodies, whether through traditional methods or with the assistance of artificial intelligence, necessitates rapid and reliable data generation. Here we introduce ...

Antibody production can slow research to a crawl. As senior vice president of Biointron, Lei Shi works with scientists around the globe to optimize and expedite their antibody projects, from start to ...

The antibody therapeutics industry is growing at an incredible pace. From early monoclonal therapeutic antibodies to modern bispecific and multispecific antibodies, single domain antibodies (VHHs), ...

“High quality, large-scale, fit-for-purpose datasets” continues to be the tagline for artificial intelligence (AI) models aiming to achieve scalable drug discovery to novel targets. While troves of ...

Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

The oPool + display platform combines technologies to make and test large numbers of antibodies at once. Antibodies are the critical targeting agents of the immune system and the crux of immune ...

The oPool+ display platform combines technologies to make and test large numbers of antibodies at once. Illinois researchers analyzed how antibodies bind to the influenza protein hemagglutinin.

Monoclonal antibodies (mAbs) are manufactured proteins that behave similarly to antibodies found naturally in the body. Researchers initially developed them for treating certain cancers but have now ...

A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the role of B cells and self-reactive antibodies in lupus, systemic sclerosis, ...